Mycoplasma pneumoniae

CDC Traveler-based Genomic Surveillance Program to Expand to Two New US International Airports in Miami and Chicago

Retrieved on: 
Tuesday, March 12, 2024
Miami International Airport, Genomics, Federation, Traveler, Pneumonia, JFK, Mycoplasma pneumoniae, Partnership, COVID-19, DNA, MIA, Bacteria, SARS-CoV-2, RSV, Ginkgo Bioworks, Biosecurity, Mycoplasma, CDC, Airport, TGS, Collection, Federal, Vaccine

This expanded funding will also bring the number of airports in the program to a total of nine active sites: Los Angeles, San Francisco, New York (JFK), Washington Dulles, Newark, Boston, Seattle, Miami, and Chicago.

Key Points: 
  • This expanded funding will also bring the number of airports in the program to a total of nine active sites: Los Angeles, San Francisco, New York (JFK), Washington Dulles, Newark, Boston, Seattle, Miami, and Chicago.
  • Since its inception in September 2021, the TGS program has demonstrated its ability to serve as an early detection mechanism for new pathogens and fill gaps in global biosurveillance.
  • In October 2023, the program expanded to cover a list of more than 30 viral and bacterial targets.
  • “We are thrilled to have the opportunity to take the TGS program to the next level.

CDC Traveler-based Genomic Surveillance Program to Expand to Two New US International Airports in Miami and Chicago

Retrieved on: 
Tuesday, March 12, 2024
O'Hare International Airport, Miami International Airport, Genomics, Federation, Traveler, Pneumonia, JFK, Mycoplasma pneumoniae, Partnership, COVID-19, Public, DNA, Bacteria, MIA, SARS-CoV-2, RSV, Ginkgo Bioworks, Federal, Biosecurity, Mycoplasma, CDC, Airport, TGS, Collection, Vaccine

BOSTON, March 12, 2024 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, the Centers for Disease Control and Prevention (CDC), and XpresCheck, by XWELL, Inc. (Nasdaq: XWEL), a leader in the delivery of onsite pathogen screening, today announced they are expanding the CDC's Traveler-based Genomic Surveillance program (TGS) to new collection locations at US international airports in Miami (MIA) and Chicago (ORD).

Key Points: 
  • This expanded funding will also bring the number of airports in the program to a total of nine active sites: Los Angeles, San Francisco, New York (JFK), Washington Dulles, Newark, Boston, Seattle, Miami, and Chicago.
  • In October 2023, the program expanded to cover a list of more than 30 viral and bacterial targets.
  • We are honored that CDC continues to trust this consortium to deliver a strategic piece of our biothreat preparedness."
  • "The additional funding of the program allows us to add infrastructure to support new mobile testing centers at Miami International Airport and Chicago O'Hare International Airport.

A pneumonia-causing bug disappeared during the pandemic – but a surge may come this winter

Retrieved on: 
Thursday, July 13, 2023
Infection, Asthma, Urinary tract infection, Kidney, Wheeze, Fever, Tonsillitis, Immunity, Brain, COVID, Diarrhea, Respiratory syncytial virus, Mycoplasma, Sinusitis, Vomiting, Epidemic, School, RSV, Hospital, Swelling, Mycoplasma pneumoniae, Mucositis, Sneeze, Bacteria, Headache, Scarlet fever, Virus, Sore throat, Pneumonia, Mouth, Fatigue, Vaccine, Pharmaceutical industry

There were record numbers of people infected with respiratory syncytial virus (RSV), flu and even strep A.

Key Points: 
  • There were record numbers of people infected with respiratory syncytial virus (RSV), flu and even strep A.
  • But the latest data suggests a surge in infections may be coming this winter.
  • It typically causes a mild chest infection, but it can cause life-threatening illness, such as pneumonia and brain swelling.
  • As with other respiratory infections, M pneumoniae is transmitted when an infected person coughs or sneezes, creating “respiratory droplets”.
  • Crowded places, such as schools and hospitals, are ideal environments for the bug to spread.

Potential resurgence

    • But, contradicting these trends, between April 2021 and March 2022 – when most other respiratory infections had made a comeback- – M pneumoniae infections remained largely absent.
    • Data from 212,207 diagnostic tests collected from 42 sites across 23 countries identified only 214 samples positive for M pneumoniae (0.1% of the samples).
    • The reasons for this lack of resurgence are not fully understood and are probably due to many factors.
    • M pneumoniae infections are known to peak and trough, with epidemics occurring every four to six years as alternative variants circulate.

SpeeDx Expand COVID-19 Diagnostics to Include Self-Collected Samples

Retrieved on: 
Thursday, April 21, 2022
Health, Infectious Diseases, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, BA1, Workflow, Real-time, Population, COVID-19, Genetic distance, STI, Respiratory syncytial virus, Mycoplasma pneumoniae, Automation, Growth, Review, Technology, GLAD-PCR assay, Clarinox Technologies Pty Ltd, Respiratory disease, Laboratory, Saliva, TGA, BA2, Mycoplasma, Partnership, Omicron, Severe acute respiratory syndrome coronavirus 2, Assessment, Vaccine

A preferred sample type for self-collection and compliance testing programs, the saliva claim will expand the utility of the SpeeDx COVID-19 workflow, and in partnership with the Molgen range of automation, will further support ultra-high throughput testing markets.

Key Points: 
  • A preferred sample type for self-collection and compliance testing programs, the saliva claim will expand the utility of the SpeeDx COVID-19 workflow, and in partnership with the Molgen range of automation, will further support ultra-high throughput testing markets.
  • Founded in 2009, SpeeDx is an Australian-based private company with subsidiary offices in Austin and London, and distributors across Europe.
  • SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management.
  • Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease.

Nabriva Announces Availability of XENLETA® (lefamulin) in a 10-Count Oral Pack

Retrieved on: 
Thursday, November 11, 2021
CYP3A4, Therapy, Moxifloxacin, CDAD, Food, COVID-19, Legionella pneumophila, Infection, Staphylococcus aureus, Review, Insomnia, Risk, Cutis laxa, Hypersensitivity, Fosfomycin, Pregnancy, Chlamydia pneumoniae, Clostridioides, Food and Drug Administration, Haemophilus influenzae, Streptococcus pneumoniae, Complicated, Research, Woman, Vomiting, Headache, Pyelonephritis, GLOBE, Tablet, Marketing, Patient, FDA, Private Securities Litigation Reform Act, NASDAQ, Fetus, CYP3A, Human, Mycoplasma pneumoniae, Liver, U.S. Securities and Exchange Commission, Arrhythmia, Nausea, Pharmacy, QT, Urinary tract infection, ABSSSI, Merck, European Union, Linezolid, Diarrhea, IV, Birth, Bacteria, Bronchopneumonia, Physician, Hypokalemia, Pharmaceutical industry, Vaccine, Birth control

XENLETA has in vitro activity and demonstrated clinical efficacy against the most common pathogens that cause community-acquired bacterial pneumonia (CABP).

Key Points: 
  • XENLETA has in vitro activity and demonstrated clinical efficacy against the most common pathogens that cause community-acquired bacterial pneumonia (CABP).
  • Our community-based sales force is excited to communicate the availability of the 10-count oral pack or X pack to their target customers.
  • XENLETA (lefamulin) is a first-in-class semi-synthetic pleuromutilin antibiotic for systemic administration in humans discovered and developed by the Nabriva Therapeutics team.
  • Efficacy of XENLETA was demonstrated in two multicenter, multinational, double-blind, double-dummy, non-inferiority trials assessing a total of 1,289 patients with CABP.